The objective of the GOREISAN-HF trial is to assess the effect of the administration of
Goreisan (TJ-17) plus standard therapy compared to standard therapy alone on the improvement
rate of cardiac edema and clinical outcomes in worsening congestive heart failure with volume
overload.